• Product NameDacomitinib (PF299804, PF299)
• Brief DescriptionInhibitors
• Purification98.00%
• Biological ActivityDacomitinib(PF299804; PF-00299804) is a potent, orally available, irreversible tyrosine kinase HER 1 (EGFR), HER2 and HER4 inhibitor with IC50 of 6, 45.7 and 73.7 nM for EGFR, ERBB2 and ERBB4, respectively.
• Target NameEGFR inhibitor
• CAS No. 1110813-31-4
• Calculated MW 469.94
• Formulation C24H25ClFN5O2
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)/C=C/CN4CCCCC4
  Pathways:Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors
  Receptor:EGFR; HER2/ErbB2; HER2/ErbB2
  Boling pt:
  Melting pt:
  Solubility:DMSO: 19 mg/mL (40.43 mM)
  Appearance:Yellow Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Engelman JA, et al, Y Res, 2007, 67(24), 11924-11932.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting